Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
ALMR Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
9.38%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Alamar Biosciences, Inc.
Market Cap
$2.55B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.43B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.66B
Return on Equity (ROE)
-8.00%
TTM Avg
-28.91%
3Y Avg
-27.68%
5Y Avg
-39.13%
Market Cap
$2.45B
Return on Equity (ROE)
71.04%
TTM Avg
-161.38%
3Y Avg
-133.53%
5Y Avg
-111.86%
Market Cap
$2.44B
Return on Equity (ROE)
-38.17%
TTM Avg
-26.66%
3Y Avg
-25.50%
5Y Avg
23.47%
Market Cap
$2.69B
Return on Equity (ROE)
-56.91%
TTM Avg
-24.13%
3Y Avg
-9.83%
5Y Avg
-11.19%
Market Cap
$2.72B
Return on Equity (ROE)
95.64%
TTM Avg
115.72%
3Y Avg
76.74%
5Y Avg
3213.80%
Market Cap
$2.40B
Return on Equity (ROE)
-4.88%
TTM Avg
-20.16%
3Y Avg
-52.49%
5Y Avg
-49.61%
Market Cap
$2.74B
Return on Equity (ROE)
-25.47%
TTM Avg
-23.80%
3Y Avg
14.67%
5Y Avg
14.67%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.55B | N/A | 9.38% | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -56.71% | -50.91% | -55.48% | -35.68% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.66B | -8.00% | -28.91% | -27.68% | -39.13% |
| Liquidia Corporation (LQDA)vs › | $2.45B | 71.04% | -161.38% | -133.53% | -111.86% |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | -38.17% | -26.66% | -25.50% | 23.47% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -56.91% | -24.13% | -9.83% | -11.19% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.72B | 95.64% | 115.72% | 76.74% | 3213.80% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -4.88% | -20.16% | -52.49% | -49.61% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.74B | -25.47% | -23.80% | 14.67% | 14.67% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.35B | 41.39% | 43.71% | 5.79% | -18.90% |
ROE
N/A
ROA
-21.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 18.76% |
| 2024-12-31 | 0.00% |
